Assay identifies actionable mutations in lymphoid malignancies

Print Friendly, PDF & Email


Researcher in the lab
Photo by Daniel Sone
Researchers say hybrid capture sequencing is an accurate and sensitive method for identifying actionable gene mutations in lymphoid malignancies. This method revealed potentially actionable mutations in 91% of patients studied, who had diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or chronic lymphocytic leukemia... [Read Article]
Print Friendly, PDF & Email

Combo is preferentially active in T-cell lymphomas

Print Friendly, PDF & Email


Lorenzo Falchi, MD
Photo by Larry Young
A 2-drug combination has demonstrated preferential activity in T-cell lymphomas over B-cell lymphomas, according to researchers. In a small, phase 1/2 study, treatment with oral 5-azacitidine and romidepsin produced a higher overall response rate (ORR) and prolonged progression-free survival (PFS) in patients with T-cell lymphomas. “In... [Read Article]
Print Friendly, PDF & Email

Combo could treat double-hit lymphoma

Print Friendly, PDF & Email


Lab mice
Photo by Aaron Logan
Existing drugs could be combined to treat double-hit lymphoma (DHL), according to preclinical research published in Science Translational Medicine. The drugs are tigecycline, an antibiotic, and venetoclax, a BCL2 inhibitor. Researchers observed promising activity with these drugs in combination, both in cell lines and mouse models of... [Read Article]
Print Friendly, PDF & Email

Risks of MGUS persist beyond 30 years

Print Friendly, PDF & Email


Malignant plasma cells
A long-term study showed that patients with monoclonal gammopathy of undetermined significance (MGUS) were still at risk of progressing to other plasma-cell or lymphoid disorders after more than 30 years of follow-up. The risk of developing such disorders was nearly 7 times higher in MGUS patients than in matched control subjects.... [Read Article]
Print Friendly, PDF & Email

CAR T-cell therapy on fast track in US, EU

Print Friendly, PDF & Email


Tisagenlecleucel (Kymriah)
Photo from Novartis
The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah, formerly CTL019) is getting fast-tracked in the United States (US) and European Union (EU). The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for tisagenlecleucel for the treatment of adults... [Read Article]
Print Friendly, PDF & Email

Generic bortezomib available in US

Print Friendly, PDF & Email


Bortezomib for Injection
Photo from Business Wire
Fresenius Kabi has introduced its generic version of Velcade, Bortezomib for Injection, to the US market. This is the first intravenous alternative to Velcade available in the US. Bortezomib for Injection is available as a single dose vial containing 3.5 mg of lyophilized powder. The product... [Read Article]
Print Friendly, PDF & Email